SAM
STRO icon

Smartleaf Asset Management’s Sutro Biopharma STRO Stock Holding History

Smartleaf Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-51
Closed -$945 – 2993
2024
Q4 		$945 Buy
51
+29
+132% +$885 ﹤0.01% 2681
2024
Q3 		$777 Buy
+22
New +$862 ﹤0.01% 2711

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Smartleaf Asset Management's STRO Position: Q1 2025 in Review

Smartleaf Asset Management sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 51 shares — an estimated $945 sold.

Smartleaf Asset Management first reported a position in STRO in Q3 2024 and held it in 2 quarters. The position peaked at $945 in Q4 2024. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Smartleaf Asset Management reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 51 Sutro Biopharma shares in Q1 2025, an estimated $945.
  • Smartleaf Asset Management first reported a position in Sutro Biopharma in Q3 2024 and held it in 2 quarters.
  • Smartleaf Asset Management's Sutro Biopharma position peaked at $945 in Q4 2024.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Smartleaf Asset Management's 13F filing for Q1 2025, filed 14 May 2025.